Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Perkovic Vlado
Jardine Meg J
Neal Bruce
Bompoint Severine
Heerspink Hiddo J L
Charytan David M.
Edwards Robert
Agarwal Rajiv
Bakris George
Bull Scott
Cannon Christopher P.
Capuano George
Kollaborációs szervezet: CREDENCE Trial Investigators
Takács Róbert
et al
Dokumentumtípus: Cikk
Megjelent: 2019
Sorozat:NEW ENGLAND JOURNAL OF MEDICINE 380 No. 24
Tárgyszavak:
doi:10.1056/NEJMoa1811744

mtmt:33677430
Online Access:http://publicatio.bibl.u-szeged.hu/26664
LEADER 03793nab a2200385 i 4500
001 publ26664
005 20230303122716.0
008 230303s2019 hu o 0|| Angol d
022 |a 0028-4793 
024 7 |a 10.1056/NEJMoa1811744  |2 doi 
024 7 |a 33677430  |2 mtmt 
040 |a SZTE Publicatio Repozitórium  |b hun 
041 |a Angol 
100 1 |a Perkovic Vlado 
245 1 0 |a Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy  |h [elektronikus dokumentum] /  |c  Perkovic Vlado 
260 |c 2019 
300 |a 2295-2306 
490 0 |a NEW ENGLAND JOURNAL OF MEDICINE  |v 380 No. 24 
520 3 |a Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes.In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin-angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically.The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P = 0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P = 0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P = 0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture.In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years. (Funded by Janssen Research and Development; CREDENCE ClinicalTrials.gov number, NCT02065791.). 
650 4 |a Klinikai orvostan 
700 0 1 |a Jardine Meg J  |e aut 
700 0 1 |a Neal Bruce  |e aut 
700 0 1 |a Bompoint Severine  |e aut 
700 0 1 |a Heerspink Hiddo J L  |e aut 
700 0 1 |a Charytan David M.  |e aut 
700 0 1 |a Edwards Robert  |e aut 
700 0 1 |a Agarwal Rajiv  |e aut 
700 0 1 |a Bakris George  |e aut 
700 0 1 |a Bull Scott  |e aut 
700 0 1 |a Cannon Christopher P.  |e aut 
700 0 1 |a Capuano George  |e aut 
700 0 2 |a Kollaborációs szervezet: CREDENCE Trial Investigators  |e aut 
700 0 2 |a Takács Róbert  |e aut 
700 0 2 |a et al.  |e aut 
856 4 0 |u http://publicatio.bibl.u-szeged.hu/26664/1/Petrovic.pdf  |z Dokumentum-elérés